Sam North
Education
Royal Australian Navy - Electronic and Communications Advanced Diploma (TAFE).
Written For
Releaf, Fast Buds, MSNL, Paradise Seeds, Cookies Seeds, Premium Cultivars
With a background in cannabis journalism - writing for Fast Buds, Paradise Seeds, Cookies Seeds Co., MSNL, and now Releaf, Sam is an experienced cannabis expert who understands how to communicate complex ideas clearly. Collaborating with clients throughout the global cannabis industry, he has cemented himself as a leading voice within both the recreational and medicinal sectors. Whether it’s researching, writing, editing, or consulting, Sam has a commitment to accuracy and quality that clients and audiences connect to. Based between Asia, Australia, and Europe, Sam is passionate about educating and enlightening people on all aspects of cannabis. By translating scientific data into easily understandable language, he strives to bridge the gap between the medical and recreational cannabis communities. Sam believes that with the proper education, correct understanding, and honest information, everyone can benefit from the natural healing power of cannabis.
Releaf articles
Green Friday UK: Releaf’s biggest ever discounts
This year, our patient survey, the largest of its kind in the UK, found that 97% of patients reported an improved quality of life and 91% they were likely to recommend medical cannabis to others who may be eiligible.
Men’s Health Month 2025: what the UK’s largest cannabis study reveals about men’s health
This Men’s Health Month, Releaf's study of active UK medical cannabis patients (the largest to date) shows how men are using treatment to improve their quality of life, reduce chronic pain, support their mental and general wellbeing, and move beyond outdated stigma. The data reflects a wider shift toward openness, ownership, and long-term health management among men seeking more stable and effective support.
Releaf expands to Germany to improve European medical cannabis access
Releaf has officially launched in Germany, marking its first international expansion and a major milestone in its mission to build Europe’s most trusted cannabis access platform. The move signals a bold step towards improving access to safe, evidence-based medical cannabis treatment across the continent.